Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015

Enferm Infecc Microbiol Clin. 2016 Oct;34(8):516.e1-516.e18. doi: 10.1016/j.eimc.2016.02.004. Epub 2016 Mar 11.

Abstract

Despite the huge advance that antiretroviral therapy represents for the prognosis of infection by the human immunodeficiency virus (HIV), opportunistic infections (OIs) continue to be a cause of morbidity and mortality in HIV-infected patients. OIs often arise because of severe immunosuppression resulting from poor adherence to antiretroviral therapy, failure of antiretroviral therapy, or unawareness of HIV infection by patients whose first clinical manifestation of AIDS is an OI. The present article updates our previous guidelines on the prevention and treatment of various OIs in HIV-infected patients, namely, infections by parasites, fungi, viruses, mycobacteria, and bacteria, as well as imported infections. The article also addresses immune reconstitution inflammatory syndrome.

Keywords: AIDS; HIV infection; Infecciones oportunistas; Infección por VIH; Opportunistic infections; Sida.

Publication types

  • Practice Guideline

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy
  • AIDS-Related Opportunistic Infections / prevention & control
  • Antiretroviral Therapy, Highly Active
  • Bacterial Infections / drug therapy
  • Coinfection
  • HIV Infections / complications*
  • Humans
  • Immune Reconstitution Inflammatory Syndrome / drug therapy
  • Immune Reconstitution Inflammatory Syndrome / prevention & control
  • Mycobacterium Infections / drug therapy
  • Mycobacterium Infections / prevention & control
  • Mycoses / drug therapy
  • Mycoses / prevention & control
  • Opportunistic Infections / drug therapy*
  • Opportunistic Infections / etiology
  • Opportunistic Infections / prevention & control*
  • Parasitic Diseases / drug therapy
  • Parasitic Diseases / prevention & control
  • Virus Diseases / drug therapy
  • Virus Diseases / prevention & control